Suppression of transthyretin expression by ribozymes

A possible therapy for familial amyloidotic polyneuropathy

Kimihiro Tanaka, Takeshi Yamada, Yasumasa Ohyagi, Hideaki Asahara, Izumi Horiuchi, Jun-Ichi Kira

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Familial amyloidotic polyneuropathy type 1 (FAP) is an autosomal-dominantly inherited disorder with systemic deposition of a variant transthyretin (TTR). We attempted to suppress TTR production by ribozyme degradation of TTR mRNA. Hammerhead and hairpin ribozymes cleaved TTR mRNA at specific individual sites in vitro. A ribozyme targeting a variant TTR (E61K) degraded the variant mRNA, but not a wild-type mRNA. These ribozymes also reduced the amounts of TTR mRNA and protein in HepG2 cells and COS-1 cells transfected with TTR-E61K cDNA. Ribozymes might be studied further as a potential treatment for FAP.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalJournal of the Neurological Sciences
Volume183
Issue number1
DOIs
Publication statusPublished - Jan 15 2001

Fingerprint

Catalytic RNA
Prealbumin
Polyneuropathies
Messenger RNA
Therapeutics
COS Cells
RNA Stability
Hep G2 Cells
Complementary DNA

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Suppression of transthyretin expression by ribozymes : A possible therapy for familial amyloidotic polyneuropathy. / Tanaka, Kimihiro; Yamada, Takeshi; Ohyagi, Yasumasa; Asahara, Hideaki; Horiuchi, Izumi; Kira, Jun-Ichi.

In: Journal of the Neurological Sciences, Vol. 183, No. 1, 15.01.2001, p. 79-84.

Research output: Contribution to journalArticle

Tanaka, Kimihiro ; Yamada, Takeshi ; Ohyagi, Yasumasa ; Asahara, Hideaki ; Horiuchi, Izumi ; Kira, Jun-Ichi. / Suppression of transthyretin expression by ribozymes : A possible therapy for familial amyloidotic polyneuropathy. In: Journal of the Neurological Sciences. 2001 ; Vol. 183, No. 1. pp. 79-84.
@article{bf0c95d7af0146b1b89ba90224e1ce49,
title = "Suppression of transthyretin expression by ribozymes: A possible therapy for familial amyloidotic polyneuropathy",
abstract = "Familial amyloidotic polyneuropathy type 1 (FAP) is an autosomal-dominantly inherited disorder with systemic deposition of a variant transthyretin (TTR). We attempted to suppress TTR production by ribozyme degradation of TTR mRNA. Hammerhead and hairpin ribozymes cleaved TTR mRNA at specific individual sites in vitro. A ribozyme targeting a variant TTR (E61K) degraded the variant mRNA, but not a wild-type mRNA. These ribozymes also reduced the amounts of TTR mRNA and protein in HepG2 cells and COS-1 cells transfected with TTR-E61K cDNA. Ribozymes might be studied further as a potential treatment for FAP.",
author = "Kimihiro Tanaka and Takeshi Yamada and Yasumasa Ohyagi and Hideaki Asahara and Izumi Horiuchi and Jun-Ichi Kira",
year = "2001",
month = "1",
day = "15",
doi = "10.1016/S0022-510X(00)00481-0",
language = "English",
volume = "183",
pages = "79--84",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Suppression of transthyretin expression by ribozymes

T2 - A possible therapy for familial amyloidotic polyneuropathy

AU - Tanaka, Kimihiro

AU - Yamada, Takeshi

AU - Ohyagi, Yasumasa

AU - Asahara, Hideaki

AU - Horiuchi, Izumi

AU - Kira, Jun-Ichi

PY - 2001/1/15

Y1 - 2001/1/15

N2 - Familial amyloidotic polyneuropathy type 1 (FAP) is an autosomal-dominantly inherited disorder with systemic deposition of a variant transthyretin (TTR). We attempted to suppress TTR production by ribozyme degradation of TTR mRNA. Hammerhead and hairpin ribozymes cleaved TTR mRNA at specific individual sites in vitro. A ribozyme targeting a variant TTR (E61K) degraded the variant mRNA, but not a wild-type mRNA. These ribozymes also reduced the amounts of TTR mRNA and protein in HepG2 cells and COS-1 cells transfected with TTR-E61K cDNA. Ribozymes might be studied further as a potential treatment for FAP.

AB - Familial amyloidotic polyneuropathy type 1 (FAP) is an autosomal-dominantly inherited disorder with systemic deposition of a variant transthyretin (TTR). We attempted to suppress TTR production by ribozyme degradation of TTR mRNA. Hammerhead and hairpin ribozymes cleaved TTR mRNA at specific individual sites in vitro. A ribozyme targeting a variant TTR (E61K) degraded the variant mRNA, but not a wild-type mRNA. These ribozymes also reduced the amounts of TTR mRNA and protein in HepG2 cells and COS-1 cells transfected with TTR-E61K cDNA. Ribozymes might be studied further as a potential treatment for FAP.

UR - http://www.scopus.com/inward/record.url?scp=0035862631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035862631&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(00)00481-0

DO - 10.1016/S0022-510X(00)00481-0

M3 - Article

VL - 183

SP - 79

EP - 84

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1

ER -